Xencor Extends U.S. Patent Term for Xtend™ Antibodies, Extending Ultomiris Royalties to 2028
I'm PortAI, I can summarize articles.
Xencor Inc. announced the extension of U.S. Patent 12,492,253 for its Xtend™ Fc domain technology, prolonging the Ultomiris® royalty term to December 2028. This extension adds approximately three years to the previous patent expiry, with expected royalty revenue exceeding $100 million to $120 million. The news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments